7 March 2018 - - Beijing, China-based biopharmaceutical company Sinovac Biotech Ltd. (NASDAQ: SVA) has taken actions to enhance the corporate governance and management of Sinovac Biotech Co., Ltd. (Sinovac Beijing), the main operating subsidiary of Sinovac, the company said.
Sinovac Biotech (Hong Kong) Ltd., a wholly owned subsidiary of the company, has appointed Dawei Mao, chairman of Zhongke Biopharmaceutical Co., Ltd., as a director of Sinovac Beijing. He has replaced Xiaomin Yang, the president of Sinobioway Group Co., Ltd.
Sinovac Biotech Ltd. focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases. Its product portfolio includes vaccines against enterovirus71, or EV71, hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), and mumps.
The company is developing a number of new products including a Sabin-strain inactivated polio vaccine, pneumococcal polysaccharides vaccine, pneumococcal conjugate vaccine and varicella vaccine.
Sinovac primarily sells its vaccines in China, while also exploring growth opportunities in international markets. The company has exported select vaccines to over 10 countries in Asia and South America.